The Board remands the issue of entitlement to an increased evaluation for prostate cancer residuals, greater than 30 percent from August 1, 2013, to December 22, 2022, due to a need for clarification regarding the Veteran's PSA findings and the determination of biochemical recurrence.
The deciding factor: Clarification is needed on the Veteran's nadir value and specific 3 PSA value points used to determine biochemical recurrence.
- Claimed conditions
- prostate cancer residuals
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- None in this decision
- Decision date
- June 12, 2025
- Citation
- 25007890
What this means for you
A remand is not a loss. The Board sent the case back for more development — often a new exam or missing records — before making a final decision. Many remands later end in a grant, and the decision spells out exactly what the Board wanted to see.
What you can do next
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Partly granted
The Board granted a 40 percent evaluation for prostate cancer residuals from January 29, 2014 to August 12, 2021.
- Denied
The Board denied the Veteran's claim for a total disability rating based on individual unemployability (TDIU) due to his service-connected disabilities, including prostate cancer residuals, hearing loss, tinnitus, and erectile dysfunction.
- Dismissed
The appeal of a proposal to reduce the rating for service-connected prostate cancer residuals from 100 percent to 40 percent is dismissed as it was not a final decision.
- Granted
The Veteran's prostate cancer residuals are granted a 60 percent rating from July 7, 2023.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.